Compile Data Set for Download or QSAR
Report error Found 15 Enz. Inhib. hit(s) with all data for entry = 12815
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730258(US20250109156, Compound 1)
Affinity DataIC50: 1nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730259(US20250109156, Compound 3)
Affinity DataIC50: 1.10nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730299(US20250109156, Compound 5)
Affinity DataIC50: 1.20nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730300(US20250109156, Compound 6)
Affinity DataIC50: 1.40nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730298(US20250109156, Compound 4)
Affinity DataIC50: 1.60nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 2 and Cyclin E1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730258(US20250109156, Compound 1)
Affinity DataIC50: 253nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 9 and Cyclin T1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730258(US20250109156, Compound 1)
Affinity DataIC50: 723nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 2 and Cyclin E1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730299(US20250109156, Compound 5)
Affinity DataIC50: 738nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 2 and Cyclin E1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730300(US20250109156, Compound 6)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 9 and Cyclin T1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730300(US20250109156, Compound 6)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 9 and Cyclin T1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730299(US20250109156, Compound 5)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 9 and Cyclin T1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730259(US20250109156, Compound 3)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 2 and Cyclin E1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730298(US20250109156, Compound 4)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 9 and Cyclin T1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730298(US20250109156, Compound 4)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetCyclin-Dependent Kinase 2 and Cyclin E1(Human)
Jiangsu Aosaikang Pharmaceutical Co.

US Patent
LigandPNGBDBM730259(US20250109156, Compound 3)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental Methods:Preparation of kinase buffer: the kinase buffer containing 50 mM HEPES, 1 mM EDTA, 10 mM MgCl2, 0.01% Brij-35, pH 7.4.2.38 g of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent